Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 13, 2024

SELL
$0.26 - $0.46 $5,460 - $9,660
-21,000 Reduced 24.92%
63,271 $17,000
Q1 2024

May 14, 2024

SELL
$0.3 - $0.46 $1,200 - $1,840
-4,000 Reduced 4.53%
84,271 $34,000
Q4 2023

Jan 26, 2024

BUY
$0.38 - $0.65 $27,842 - $47,626
73,271 Added 488.47%
88,271 $36,000
Q3 2023

Nov 13, 2023

SELL
$0.29 - $0.63 $15,804 - $34,335
-54,500 Reduced 78.42%
15,000 $7,000
Q2 2023

Aug 14, 2023

BUY
$0.23 - $0.39 $4,830 - $8,190
21,000 Added 43.3%
69,500 $26,000
Q4 2022

Feb 15, 2023

SELL
$0.26 - $0.64 $2,860 - $7,040
-11,000 Reduced 18.49%
48,500 $14,000
Q3 2022

Nov 10, 2022

BUY
$0.48 - $1.11 $28,560 - $66,045
59,500 New
59,500 $29,000

Others Institutions Holding CYBN

About CYBIN INC.


  • Ticker CYBN
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 166,120,000
  • Market Cap $2.07B
  • Description
  • Cybin Inc., a biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine for treating anxiety disorders; and CYB005, a phenethylamine derivative to t...
More about CYBN
Track This Portfolio

Track Cerity Partners LLC Portfolio

Follow Cerity Partners LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cerity Partners LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cerity Partners LLC with notifications on news.